Haniel Araujo: Efficacy of the novel RAS(ON) in KRASG12C mutant NSCLC
Haniel Araujo, Thoracic and Head and Neck Medical Oncology Fellow at MD Anderson Cancer Center, shared on X:
“Thrilled to share our findings on the efficacy of the novel RAS(ON) multi-selective inhibitor RMC-7977 in difficult-to-treat KRASG12C mutant NSCLC and mechanisms of tolerance to RAS inhibition. Check our paper in Cancer Discovery!
‘Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC‘
Authors: Haniel A. Araujo, Ximo Pechuan-Jorge, Teng Zhou, Minh Truong Do, Xin Hu, Frank R. Rojas Alvarez, Maria E. Salvatierra, Heladio P. Ibarguen, Richard Lee, Rashi Raghulan, Harshit Shah, Mariela A. Moreno Ayala, Kevin Chen, Nataliya, Tovbis Shifrin, Shuhong Wu, Luisa M. Solis Soto, Marcelo V. Negrao, Don L. Gibbons, David S. Hong, Jack A. Roth, John V. Heymach, Jianjun Zhang, Jingjing Jiang, Mallika Singh, Jacqueline A. M. Smith, Elsa Quintana, Ferdinandos Skoulidis.
Source: Haniel Araujo/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023